Daniel A. Pollyea, MD, MS, associate professor of medicine and clinical director of Leukemia Services at the University of Colorado School of Medicine, discusses some of the recent advancements in acute myeloid leukemia. Pollyea says researchers have been able to create more personalized treatments for many patients by doing targeted sequencing of patient samples.
Daniel A. Pollyea, MD, MS, associate professor of medicine and clinical director of Leukemia Services at the University of Colorado School of Medicine, discusses some of the recent advancements in acute myeloid leukemia (AML). Pollyea says researchers have been able to create more personalized treatments for many patients by doing targeted sequencing of patient samples.
There are many exciting advances that are both here now and on the horizon, Pollyea notes. Some of these advancements include targeted therapies based on protein expression. The key is to target the patient’s immune system so that the patient can kill the tumor themselves, Pollyea explains.
Cretostimogene Grenadenorepvec Shows High CR Rate in BCG-Unresponsive NMIBC
July 17th 2024Mark D. Tyson, II, MD, MPH, discussed treatment with cretostimogene grenadenorepvec in high-risk Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer with carcinoma in situ and data from the BOND-003 trial.
Read More
Phase 3 VERIFY Trial Investigates Rusfertide’s Potential in Polycythemia Vera
July 16th 2024In an interview, Aniket Bankar, MD, discussed the background, design, and goals of the phase 3 VERIFY trial of the hepcidin mimetic rusfertide for the treatment of patients with polycythemia vera.
Read More
FDA Enforces Partial Hold on Trial of Seclidemstat in MDS/CMML
July 16th 2024Following the report of a serious and unexpected grade 4 adverse effect, a partial clinical hold has been placed on the phase 1 trial evaluating seclidemstat with azacitidine in myelodysplastic syndrome and chronic myelomonocytic leukemia.
Read More